Funds holding MEREO BIOPHARMA GROUP PLC
ISIN US5894921072 · United Kingdom · LEI 213800U8JQHIJOS5AS09
- Fund holders
- 4
- Of which ETFs
- 2 2 other funds
- Value held
- 112.8K $
| Fund | Shares | Value | Weight in fund | |
|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) International Small Cap ETF SPDR INDEX SHARES FUNDS | 133,379 | 44K $ | 0.01 % | as of Mar 31, 2026 ↗ |
| Virtus Biotech Clinical Trials Etf ETFis Series Trust I | 127,193 | 34.1K $ | 0.09 % | as of Apr 30, 2026 ↗ |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 92,534 | 34.3K $ | 0.00 % | as of Feb 28, 2026 ↗ |
| Blackstone Alternative Multi-Strategy Fund Blackstone Alternative Investment Funds | 1,200 | 396 $ | as of Mar 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table counts shares; this one measures what the company weighs inside each fund.
| Fund | Weight in fund | |
|---|---|---|
| Virtus Biotech Clinical Trials Etf ETFis Series Trust I | 0.09 % | as of Apr 30, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) International Small Cap ETF SPDR INDEX SHARES FUNDS | 0.01 % | as of Mar 31, 2026 ↗ |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 0.00 % | as of Feb 28, 2026 ↗ |
Quarter after quarter
Each SEC quarterly data set, newest first. The change is read against the quarter before it.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 4 | -2 | 354,306 | -47.9 % |
| 2026Q1 | 6 | -3 | 679,424 | -69.9 % |
| 2025Q4 | 9 | -1 | 2,259,852 | -2.8 % |
| 2025Q3 | 10 | +2 | 2,326,088 | +35.8 % |
| 2025Q2 | 8 | 0 | 1,713,125 | +34.1 % |
| 2025Q1 | 8 | +1 | 1,277,386 | +22.7 % |
| 2024Q4 | 7 | 0 | 1,041,478 | +16.2 % |
| 2024Q3 | 7 | -4 | 896,011 | +12.5 % |
| 2024Q2 | 11 | +4 | 796,281 | +66.0 % |
| 2024Q1 | 7 | +2 | 479,677 | +258.3 % |
| 2023Q4 | 5 | 133,889 |
Institutional managers
61 managers declare this company to the SEC (Form 13F); the 25 largest follow.
| Manager | Shares | Value | |
|---|---|---|---|
| Rubric Capital Management LP | 15,307,347 | 5.1M $ | as of Mar 31, 2026 |
| EcoR1 Capital, LLC | 13,368,855 | 4.4M $ | as of Mar 31, 2026 |
| 683 Capital Management, LLC | 12,000,000 | 4M $ | as of Mar 31, 2026 |
| BANK OF AMERICA CORP /DE/ | 8,195,287 | 2.7M $ | as of Mar 31, 2026 |
| Defilade Capital Management, L.P. | 7,558,756 | 2.5M $ | as of Mar 31, 2026 |
| Newtyn Management, LLC | 7,079,056 | 2.3M $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 3,559,103 | 1.2M $ | as of Mar 31, 2026 |
| Tejara Capital Ltd | 2,037,520 | 672.4K $ | as of Mar 31, 2026 |
| UBS Group AG | 1,490,128 | 491.7K $ | as of Mar 31, 2026 |
| Wealthspire Advisors, LLC | 796,036 | 262.7K $ | as of Mar 31, 2026 |
| MARSHALL WACE, LLP | 686,987 | 226.7K $ | as of Mar 31, 2026 |
| GROUP ONE TRADING LLC | 335,827 | 110.8K $ | as of Mar 31, 2026 |
| Rangeley Capital, LLC | 329,200 | 108.6K $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 302,991 | 100K $ | as of Mar 31, 2026 |
| Knott David M Jr | 300,337 | 99.1K $ | as of Mar 31, 2026 |
| ACADIAN ASSET MANAGEMENT LLC | 209,084 | 68 $ | as of Mar 31, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 195,920 | 64.7K $ | as of Mar 31, 2026 |
| TWO SIGMA INVESTMENTS, LP | 187,839 | 62K $ | as of Mar 31, 2026 |
| ADAR1 Capital Management, LLC | 150,000 | 49.5K $ | as of Mar 31, 2026 |
| JANE STREET GROUP, LLC | 139,973 | 46.2K $ | as of Mar 31, 2026 |
| STATE STREET CORP | 133,379 | 44K $ | as of Mar 31, 2026 |
| Forefront Analytics, LLC | 127,778 | 42.2K $ | as of Mar 31, 2026 |
| Virtus Investment Advisers, LLC | 125,662 | 41.5K $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 92,534 | 30.5K $ | as of Mar 31, 2026 |
| XTX Topco Ltd | 84,469 | 27.9K $ | as of Mar 31, 2026 |
Declared shareholders of MEREO BIOPHARMA GROUP PLC
1 beneficial ownership filing. These stakes do not add up: an asset manager filing aggregates its own funds, already counted above.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| EcoR1 Capital, LLC and 2 others | 8.40 % | 66,844,275 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding MEREO BIOPHARMA GROUP PLC". https://titelia.com/en/stocks/mereo-biopharma-group-plc-US5894921072